



## REGENXBIO to Present at Upcoming Investor Conferences

November 06, 2018 08:00 AM EST

ROCKVILLE, Md., Nov. 6, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced that it will present at the following November investor conferences:

### **Credit Suisse 27<sup>th</sup> Annual Healthcare Conference**

**Date:** Tuesday, November 13, 2018

**Location:** The Phoenician Hotel, Scottsdale, AZ

**Presentation:** Tuesday, November 13, 2018 at 8:35 a.m. MT

### **Barclays Gene Editing & Gene Therapy Summit**

**Date:** Thursday, November 29, 2018

**Location:** Barclays, New York, NY

**Presentation:** Thursday, November 29, 2018 at 11:45 a.m. ET

A live webcast of the Credit Suisse presentation can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcast will be available on the same website for approximately 30 days following each presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

### **About REGENXBIO**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV<sup>®</sup> Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### **CONTACT:**

#### **Investors**

Natalie Wildenrad, 646-681-8192

[natalie@argotpartners.com](mailto:natalie@argotpartners.com)

#### **Media**

Adam Pawluk, 202-591-4063

[apawluk@jpa.com](mailto:apawluk@jpa.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-300744177.html>

SOURCE REGENXBIO Inc.